Please login to the form below

Not currently logged in
Email:
Password:

Mirna hires former Pfizer director as CMO

Dr Sinil Kim has extensive experience in oncology

Mirna Therapeutics Sinil KimDr Sinil Kim has left his position as a senior director at Pfizer to join Mirna Therapeutics as chief medical officer and senior VP, oncology.

Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time at Pfizer.

Prior to this, he was director of clinical oncology at Bristol-Myers Squibb where he worked on the clinical development of Erbitux (cetuximab), which is approved for colorectal cancer and head and neck cancer.

His additional experience includes being co-founder of DepoTech, where he invented several liposomal drug products, including DepoCyt (cytarabine liposome injection), DepoDur (morphine sulfate extended-release liposome injection) and Exparel (bupivacaine liposome injectable suspension).

This background will benefit Mirna, which has just started phase I trials for its lead oncology candidate MRX34 – the first micro-RNA product to enter a clinical trial in cancer.

Dr Paul Lammers, president and CEO of Mirna, commented: “The depth and breadth of Sinil's clinical and regulatory expertise in oncology, as well as his reputation as a respected industry executive responsible for successfully developing multiple marketed oncology products, will be of significant value to our clinical team as we work together to strengthen our leadership in the development of miRNA-based therapeutics as a promising new class of anticancer agents.”

6th June 2013

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

digital launch
How can virtual pharma companies de-risk new product launches?
The risks and challenges involved in taking specialty drugs, biopharmaceuticals and drug/device combinations to market...
Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...

Infographics